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SUMMARY
Salmonella Typhimurium (S.Tm) causes acute enter-
opathy resolving after 4–7 days. Strikingly, antibiotic
therapy does not accelerate disease resolution.
We screened for factors blocking remission using a
S.Tm enterocolitis model. The antibiotic ciprofloxa-
cin clears pathogen stool loads within 3–24 hr, while
gut pathology resolves more slowly (c50: 48 hr,
remission: 6–9 days). This delayed resolution is
mediated by an interferon-g (IFN-g)-dependent
response that is triggered during acute infection
and continues throughout therapy. Specifically,
IFN-g production by mucosal T and NK cells retards
disease resolution by maintaining signaling through
the transcriptional regulator STAT1 and boosting
expression of inflammatory mediators like IL-1b,
TNF, and iNOS. Additionally, sustained IFN-g fosters
phagocyte accumulation and hampers antimicrobial
defense mediated by IL-22 and the lectin REGIIIb.
These findings reveal a role for IFN-g in delaying
resolution of intestinal inflammation and may inform
therapies for acute Salmonella enteropathy, chronic
inflammatory bowel diseases, or disease resolution
during antibiotic treatment.
INTRODUCTION
Non-typhoidal salmonellosis (NTS) is among the main causes
of bacterial diarrhea worldwide (Kirk et al., 2015). Infection with
NTS strains like S. Typhimurium (S.Tm) typically causes acute,
self-limiting inflammatory gastroenteritis in man. Infants aged
<3 months, the elderly aged R60 years and immunocompro-
mised individuals are at risk of systemic pathogen spread that
warrants antimicrobial therapy (Onwuezobe et al., 2012). Cipro-
floxacin, a third-generation 5-fluoroquinolone is commonly used
against both Gram positives and negatives, including systemic
NTS infections (Sirinavin and Garner, 2000). Despite its merits
in containing systemic infection and ablating fecal shedding,
the antibiotic therapy of NTS diarrhea is surprisingly ineffective
in reducing the disease symptoms of acute gastroenteritis
(Onwuezobe et al., 2012). The mechanistic underpinnings have
remained obscure.
The gut mucosa provides an effective barrier against the
outer world of microbial habitats. Maintenance of mucosal
homeostasis relies on a delicate network of interactions
between the microbiota, the stromal compartments, and the
gut-associated immune system (Germain, 2012). From birth
on, this system evolves in response to the encountered mi-
crobes toward an equilibrium that establishes a physiological
and immunological superorganism defined by the coexistence
of host and its microbes (Eberl, 2010). In the case of acute
infections, which often involve pronounced mucosal perturba-
tions, recovery not only requires pathogen elimination, but
also relies on mechanisms to resolve inflammation. It has often
been assumed that pathogen clearance and the resolution of
inflammation should go hand in hand, as resolution kinetics
are controlled by the removal of microbe-derived stimuli
(Buckley et al., 2013); otherwise, chronic inflammation, or
even mortality, may result due to an uncontrolled cytokine
storm (Gros and Belkaid, 2014). Indeed, studies of self-limiting
acute inflammatory responses led to the discovery of special-
ized pro-resolving mediators, whose role during the resolution
of inflammation has been well established (Chiang et al., 2012;
Serhan, 2014). In spite of this progress, the mechanisms con-
trolling remission in the intestinal mucosa have not been fully
understood. This includes the failure of antibiotics to relieve
enteropathy inflicted by acute NTS diarrhea (Onwuezobe
et al., 2012).
Here, we used a murine Salmonella diarrhea model (Kaiser
et al., 2012) to study the factors limiting resolution during cipro-
floxacin therapy. We analyzed resolution kinetics using morpho-
logical, cellular, and molecular parameters. Our results delineate
how mucosal remission proceeds following pathogen clearance
and identified an unresolved interferon (IFN)-g-driven pro-in-
flammatory program that hinders mucosal recovery from acute
gut infection.
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RESULTS
A Mucosal Remission Model for NTS Enteritis
In the streptomycin mouse model (Kaiser et al., 2012), Bl6 mice
infected with S.Tm SL1344 develop enteropathy 12 hr post
infection (p.i.). If left untreated, the animals succumb to infection
at approximately day 5 p.i. Here, we asked whether antibiotic
therapy would not only reduce pathogen loads, but also atten-
uate pathology and result in resolution of acute mucosal inflam-
mation (Figure 1A). Mice were infected with wild-type (WT) S.Tm
(5 3 107 colony-forming unit [CFU] by gavage) and treated with
ciprofloxacin from day 1 p.i. up to day 10 p.i. (Figure 1B, (Kaiser
et al., 2014)). Antibiotic therapy reduces gut luminal S.Tm loads
by 107-fold within 3 hr and prevents pathogen spread to the
spleen (Kaiser et al., 2014). Importantly, gut luminal pathogen
loads remained below detection, as long as the antibiotic treat-
ment was continued (Figure 1C).
Next, we assessed the resolution of mucosal pathology. In
acute self-limiting peritonitis, the resolution interval (Ri) defines
the transition time from maximal (Jmax) to half-maximal inflam-
mation (J50) (Chiang et al., 2012). In analogy, we assessed
macroscopic organ morphology and histopathological scoring
of the infected cecal tissue at day 1 p.i. to define Jmax. The
macroscopic shrinking of the cecum tissue (Figures 1D and 1E)
and the microscopic assessment of tissue histopathology
(Figures 1F and 1G) yielded equivalent resolution kinetics
reachingJ50 within48 hr and resolution to normal levels within
6–9 days of therapy (Figure 1H). However, it remains to be estab-
lished which cellular andmolecular parameters impact on remis-
sion under these conditions.
Transcriptional Response of the Resolving Cecal
Mucosa during Therapy
To begin our mechanistic analysis of remission, we performed
transcriptional profiling of the cecal tissue. Gene expression of
52 inflammatory cytokines, chemokines, and antimicrobial effec-
tors was quantified using a real-time qPCR array (four mice per
group; Table S1). Some of these candidates were known to be
induced during acute S.Tm infection (Godinez et al., 2008). Our
quantitative approach verified the robust expression of many
pro-inflammatory genes atJmax (Figure 2A, dark blue) and iden-
tified their remission kinetics during antibiotic therapy. Hierarchi-
cal clustering identified five gene clusters (0.95 p value threshold
via multiscale bootstrap resampling; Figures 2B, S1A, and S1B).
Cluster 1 comprised of 25 genes characterized by induction at
Jmax, and moderate or no remission during therapy (Figures
2A and 2B). In line with the enteropathy data (Figures 1D–1H),
many of these genes (e.g., Ifng, Il1b, Tnf, Il6, andCxcl10) are typi-
cally induced in highly inflamed tissues. The data were corrobo-
rated by real-time qPCR assays (e.g., Figures 2C and 2D). Genes
within clusters 2–4 were either mildly regulated or non-respon-
sive (Figure S1C). Finally, principal-component analysis of the
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Figure 1. Resolution Kinetics of Mucosal Inflammation during Antibiotic Therapy of Acute S. Typhimurium Infection
(A) Schematic illustrating remission scenarios.
(B) Experimental procedure: Bl6 mice were orally infected with 5 3 107 CFU S.Tm and treated with ciprofloxacin per os from day 1 p.i.
(C) S.Tm load in cecal content.
(D) Cecal/colonic macropathology.
(E) Cecal index determined as body weight/excised cecal organ weight.
(F) Histopathology scoring of cecal tissue.
(G) H&E-stained cecal tissue sections. Scale bar, 100 mm.
(H) Remission kinetics of murine S.Tm colitis. Summary graphs show n = 5–9 mice from two to five independent experiments as mean ± SD.
Statistical significance was calculated via the Mann-Whitney U test. 1, mice w/o sm; p.i., post-infection; n.d., not detectable; +cip, oral ciprofloxacin
treatment; -inf, only treatment, no infection; -cip, only infection, no treatment;Jmax, inflammation at day 1 p.i.;J50, 50% ofJmax; lu, lumen; mu, mucosa; sme,
submucosal edema; y, death.
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expression profiles indicated clear differences between naive
mice, mice at Jmax, and mice during antibiotic therapy. Strik-
ingly, the latter clustered together, nomatter whether the therapy
was applied for 1, 2, 4, or 9 days (Figure 2E). This suggested
that an unresolved pro-inflammatory program persisted during
the course of therapy. We reasoned that these unresolved
responses might be of key importance for understanding why
antibiotic treatment has proven inefficient at treating non-
complicated cases of NTS diarrhea.
Interestingly, cluster 1 included several antimicrobial peptides,
a fundamental arm of the mucosal innate immune defense (Bev-
ins and Salzman, 2011). Antimicrobials secreted in high amounts
are also critical biomarkers of adjunct diagnostics during infec-
tious gastroenteritis (Figure S1D; (Gonzalez et al., 2015)). Among
the antimicrobial genes of cluster 1, S100a9 and Lcn2 (typically
expressed by polymorphonuclear cells [PMNs]) were 100- to
1,000-fold induced atJmax. Their expression decreased signifi-
cantly (though not completely) during therapy (Figures 2F and
S1E). This was reminiscent of the remission kinetics shown in
Figures 1E and 1G. In contrast, expression of epithelial-derived
C-type lectinsReg3b andReg3g continued to rise during the first
2 days of therapy and remained high to the end (Figures 2G and
S1E). These data pointed to an underlying immune activation,
which did not resolve with mucosal histopathology. Initially, we
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Figure 2. Mucosal Gene Expression, Microbes, and Barrier Function during Antibiotic Therapy of Acute S.Tm Colitis
(A) Expression heatmap of 52 pro-inflammatory and antimicrobial genes. Colors, indicate fold change of DCq versus day1; data are sorted as highest/ lowest
at d1 p.i.
(B) Hierarchical clustering of data from (A) (full list: Table S1).
(C and D) Il6 (C) and Tgfb3 (D) transcript levels.
(E) Principal component analysis of all 52 genes from naive mice (d-1; black) or mice during infection (black) and therapy (red).
(F and G) Lcn2 (F) and Reg3b (G) transcript levels. Significance is tested versus d-1 (C, D, F, and G).
(H) Micrographs of cecal sections. Scale bar, 10 mm.
(I) Total bacterial density in cecal content quantified by FACS.
(J and K) Epithelial barrier function in naive and DSS-treated controls compared to infected mice after 2 days of antibiotic therapy. (J) Serum albumin in cecal
content determined by ELISA. (K) FITC fluorescence in serum.
Summary graphs show five to eight individual mice pooled from two to t hree independent experiments as mean ± SD. Statistical significance was analyzed via
the Mann-Whitney U test. 1, mice w/o sm, cip, or S.Tm; +cip, oral ciprofloxacin treatment; -inf, only treatment, no infection; -cip, only infection, no treatment;
n.s., not significant; lu, lumen; mu, mucosa.
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speculated that a compromised barrier or the up-growth of un-
identified microbes might be involved.
To assess microbial content, we analyzed tissue sections by
SYTOX Green and anti-Salmonella O antigen group B antibody
staining. At Jmax, high numbers of S.Tm were present at the
mucosal interface and in the lumen (Figure 2H). Importantly, no
S.Tm was detected within the gut lumen, and gut tissue loads
were strongly reduced during therapy (Figures 1C, 2H, and
S1F). SYTOX Green staining and microscopy or fluorescence-
activated cell sorting (FACS) detected a dense microbial com-
munity in untreated mice, which was reduced during ciprofloxa-
cin therapy (Figures 2H, 2I, and S1F). Among the remaining
microbes, 16S sequencing did not identify species with known
virulence potential (Table S2). Thus, pathobiont blooms are not
a likely cause of the slow remission.
Additionally, we assessed intestinal permeability bymeasuring
serum albumin levels in the fecal pellets, or fluorescein isothiocy-
anate (FITC)-dextran in the serum after oral gavage (Figure S1G).
In contrast to dextran sodium sulfate (DSS)-induced colitis (pos-
itive control), S.Tm-infected mice did not show evidence of
increased intestinal permeability at day 2 of ciprofloxacin therapy
(Figures2Jand2K). Thus, compromisedbarrier functiondoesnot
seem to explain why appreciable levels of mucosal inflammation
remain during antibiotic therapy.
Hence, other causes were likely involved. The fact that some
cluster 1 genes remained highly expressed throughout the
therapy suggested a role for innate mechanisms. We therefore
reasoned that the cellular dynamics of myeloid infiltrates or
lymphoid regulators may be a key to unravel the underlying
mechanisms of remission during therapy.
The Myelomonocytic Compartment: Responders to
Acute Gut Inflammation and Resolution
To evaluate the composition of myeloid cells during therapy, we
used fractalkine receptor CX3CR1-GFP reporter mice that allow
detailed identification of intestinal mononuclear phagocytes
(Jung et al., 2000; Tamoutounour et al., 2012). Additionally, we
devised a purification procedure that allowed isolation of lamina
propria cells from the cecal mucosa (1) to assess cell composi-
tion and (2) to enable intracellular detection of regulatory cyto-
kines (see Experimental Procedures; Figure 3A; Table S3; Fig-
ures S2A and S2B).
Our analysis focused on day 2 of the therapy (day 3 p.i.), when
pathogen loads are diminished and the mucosa begins to
recover (J50). In the absence of therapy, Ly-6G
+ neutrophils
massively accumulated in the cecal mucosa by days 1–3 p.i.
(Figures 3B and 3C; Figures S2C–S2G). Importantly, antibiotic
treatment reduced the abundance of these granulocytes in the
cecal mucosa (Figures 3B, 3C, and S2C–S2E). Among the
phagocytic mononuclear leukocytes, Ly-6Chi monocyte-derived
cells (MCs) were particularly prominent at day 1 p.i. (Figure 3D).
In this subset of CD103– CX3CR1
+ myeloids, we observed pro-
nounced differentiation into Ly-6C+ MHCII+ (MCint) and Ly-6C–
MHCII+ macrophages (mac; Figures 3D and 3E), a process
dubbed as the ‘‘monocyte waterfall’’ (Figures 3A, S2H, and
S2I) (Tamoutounour et al., 2012). The abundance of the inflam-
matory MCint cells was significantly reduced after 2 days of anti-
biotic therapy (J50), and this coincided with the accumulation of
differentiated Ly-6C– MHCII+ mac (Figures 3D and 3E). A high
proportion of MHCII+ mac was also observed in the resting cecal
mucosa, though at much lower numbers of CD103– CX3CR1
+
myeloids (Figures 3A and 3E). These MHCII+ mac belong to the
tissue-resident mononuclear phagocyte system (MPS) that are
known to maintain homeostasis in the resting gut mucosa
(Bain and Mowat, 2011). Thus, the composition of PMN and
MC-derived myeloids in the resolving cecal mucosa were in
line with the histopathology time course (Figures 1F and 1G),
suggesting that these cell populations began to normalize and
slowly return to the situation of the unperturbed gut (Figures
3B–3E).
Next, we analyzed the functional properties of cecal mononu-
clear phagocytes (MNPs). To date, two distinct functional states
of macrophage activation have been recognized. Microbial
moieties and Th1 cytokines, like IFN-g, polarize macrophages
toward an M1 phenotype associated with NF-kB and STAT1
signaling that boosts expression of the chemokines CXCL9-10,
the cytokines interleukin-1b (IL-1b), and tumor necrosis factor
(TNF). In contrast, tissue remodeling during wound healing is
orchestrated by M2 macrophages requiring PPAR-g and Stat6
signaling (Murray and Wynn, 2011). While freshly extravasated
blood monocytes create a highly antimicrobial and inflammatory
M1-like environment, resident intestinal macrophages are clearly
different from the M1 and M2 populations as they are highly
phagocytic and do not express arginase, and an essential source
of IL-10 (Bain and Mowat, 2011). To assess such functional
phenotypes of MNPs during remission, we measured the overall
transcript levels of the M1-type signals Il1b, Tnf, and Nos2 in the
cecal tissue. The infection with S.Tm drastically increased the
expression of these mediators at day 1 p.i. (Figures 3F and
S2J). After two days of antibiotic therapy, Il1b and Tnf levels
declined by >2-fold (Figure 3F), while the expression of Nos2
remained unchanged (Figure S2J). To study this in more detail,
highly purified CD11b+ CX3CR1
+ myeloid cells were isolated
by cell sorting and analyzed by real-time qPCR. After 2 days of
antibiotic therapy, Il1b and Tnf expression by CX3CR1
+ MNPs
declined, while the expression ofNos2 and the anti-inflammatory
Il10 increased (Figure 3G). This verified that the resolving cecal
mucosa accumulates Ly-6C– MHCII+ intestinal macrophages,
which are characteristic for mucosal homeostasis (Figures 3A
and 3E).
In a complementary approach, we analyzed mucosal STAT1
signaling that regulates pro-inflammatory M1 activity. Immuno-
histochemistry of cecal tissue sections revealed that S.Tm
boosts phosphorylated STAT1 levels by day 1 p.i., in particular
in cells of the lamina propria (red arrowheads; Figure 3H). Quan-
titative western blot analysis confirmed that pY701 STAT1 highly
accumulated by day 1 p.i., while antibiotic therapy reduced the
relative abundance of pY701 in the gut mucosa (Figure 3I). These
data are consistent with our hypothesis that antibiotic therapy
results in a significant, but incomplete restoration of MNP ho-
meostasis. However, it remains to be shown how this may affect
remission kinetics.
Extent of Resolution Is Controlled by an
IFN-g-Dependent Program
The factors controlling mucosal recovery during antibiotic ther-
apy remains to be identified. We speculated that two different
phenomena might be involved: (1) persistent bacteria, which
Cell Host & Microbe 20, 238–249, August 10, 2016 241
survive the antibiotic therapy in the gut tissue (Diard et al., 2014;
Kaiser et al., 2014), might elicit sustained pro-inflammatory
responses and thereby delay remission, or (2) an unidentified
program of the mucosal immune system that hinders resolution
kinetics independent of pathogen loads.
First, we determined the number of persistent bacteria that
survive in the cecum tissue during ciprofloxacin therapy. Plating
and microscopic enumeration of intracellular bacteria residing
in the cecal mucosa established that S.Tm tissue loads were
reduced by 50- to 1,000-fold during therapy (Figures 4A and
4B). Further reducing the load of S.Tm persisters by combined
therapy (i.e., by treating with a second antibiotic, ceftriaxone)
did not enhance resolution (Figures 4E–4J). Thus, persistent
pathogen cells remaining in the gut tissue do not seem to limit
remission kinetics during ciprofloxacin therapy.
To pinpoint potential molecular candidates that may delay
remission, we performed a volcano plot analysis of the cecal mu-
cosa transcriptional profiles from Figures 2A and 2B. Transcripts
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Figure 3. Mucosal Myeloid Responses during Acute Gut Inflammation and Antibiotic Therapy
(A–E) CX3CR1-GFPmice were infected as in Figure 1. (A) Myeloid subsets in the naive cecal mucosa. (Full list is shown in Table S3.) (B and C) Ly-6G
+ neutrophils.
(D and E) Monocyte waterfall cells. MC: Ly-6Chi MHCII–/ MCint: Ly-6C+ MHCII+/ mac: Ly-6C– MHCII+.
(F) Il1b and Tnf transcript levels.
(G) Il1b, Tnf, Nos2, and Il10 transcript levels of purified CD11b+ CX3CR1
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(H) Phospho-STAT1 (Y701) immunohistology of cecal tissue sections. Red arrowheads: lamina propria cells. Scale bar, 50 mm.
(I) Western blot analysis of pY701 STAT1, STAT1, and GAPDH. 0, below detection limit.
Summary graphs show five to seven individual mice pooled from two to five independent experiments as mean ± SD. Statistical significance was analyzed via
the Mann-Whitney U test. neu, neutrophil; cDC, type 1/2 conventional dendritic cell; MC, monocyte-derived cell; mac, macrophage; MCint, MC-mac
intermediate;1, micew/o sm; +cip, oral ciprofloxacin treatment; -inf, only treatment, no infection; -cip, only infection, no treatment; lu, lumen;mu,mucosa; sme,
submucosal edema.
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remaining at a relatively high level atJ50 included CXCL-chemo-
kines, AMPs, as well as IFN-g and IL-22. In fact, IFN-g was the
most prominent cytokine at the transcriptional level by day 3
and 5 p.i. (Figures 4C and S3A). It showed a typical cluster 1
signature with >100-fold induction at day 1 p.i. and sustained
high expression remaining at least 30-fold above the homeo-
static level during the course of therapy (Figure 4D). To assess
whether IFN-gmight limit remission kinetics, we determined res-
olution indices in the face of compromised IFN-g signaling (i.e., in
Ifng/ or Ifngr1/ mice), or alternatively by antibody-mediated
IFN-g neutralization during ciprofloxacin therapy (Figure 4E).
While IFN-g deficiency did not affect antibiotic-mediated clear-
ance of gut luminal bacteria, it resulted in elevated loads of
persistent bacteria at systemic sites in genetically susceptible
Ifng/ and Ifngr1/ mice (Figures 4F and 4G). Surprisingly,
this was not observed in mice treated with ciprofloxacin and
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Figure 4. IFN-g Hinders Mucosal Remission
(A and B) S.Tm tissue load determined by plating (black) or fluorescence microscopy (green). Scale bar, 50 mm.
(C) Volcano plot analysis of Figure 2A data correlating relative expression and significance. Red, top eight hits.
(D) Ifng transcript levels. Significance was assessed versus d-1.
(E) Tested experimental groups in (F)–(O).
(F) S.Tm loads in cecal content.
(G) S.Tm loads in mesenteric lymph nodes.
(H and I) Histopathology scoring of cecal tissue. Scale bar, 100 mm.
(J and K) S.Tm tissue load determined by plating.
(L) S.Tm tissue load depicted by fluorescence microscopy. Scale bar, 50 mm.
(M) Il22 and Reg3b transcript levels.
(K and M) REGIIIb as detected in cecum content by western blots.
(N and O) Histopathology scoring of cecal tissue. Scale bar, 100 mm.
Summary graphs show five to eight individual mice pooled from two to five independent experiments as mean ± SD. Statistical significance was analyzed via the
Mann-Whitney U test.1, mice w/o sm; +cip, oral ciprofloxacin treatment; -inf, only treatment, no infection; -cip, only infection, no treatment; n.s., not significant;
cef, ceftriaxone treatment; aIFN-g, aIL-22, neutralizing antibodies; lu, lumen; mu, mucosa; sme, submucosal edema.
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IFN-g-neutralizing antibodies (Figure 4G). We speculate that
IFN-g is critical during the first day to restrict pathogen trafficking
to systemic sites. Most importantly, however, mucosal inflam-
mation was reduced in all groups of IFN-g-impaired animals
(Figures 4H and 4I). The expression of characteristic pro- or
anti-inflammatory mediators (e.g., Il6, Il17a, Il10) remained un-
changed and IL-10 deficiency did not affect mucosal inflamma-
tion (Figures S3C–S3F). Thus, it remained unclear how IFN-g
affects remission.
First, we determined persistent bacterial loads in the IFN-g
impaired mucosa. Ifng/ animals, despite featuring elevated
counts in the mesenteric lymph node (mLN) (Figure 4G), had
equivalent gut tissue loads compared to WT mice (Figure 4J).
We speculated that the effect of such tissue-specific pathogen
control might root in the regulation of antimicrobial host de-
fenses. While the mucosal expression of S100a9 showed no sig-
nificant difference (Figure S3G), REGIIIb expression was further
elevated in the absence of IFN-g signaling (Figure 4M). These
data suggested that epithelial REGIIIb levels may compensate
for the reduced antimicrobial activity of myeloid cells (that is typi-
cally observed under systemic IFN-g deficiency) and thereby
explain why mucosal pathogen loads of WT and IFN-g-deficient
mice do not differ after 2 days of ciprofloxacin therapy.
Next, we assessed IL-22. Lymphoid cell-derived IL-22 is a key
regulator to boost the expression of REGIII family C-type lectins
(which can limit S.Tm growth; Figure S3, legend) in the gut and
the lung epithelium (Sonnenberg et al., 2011). Accordingly,
IL-22-deficient animals featured reduced levels of REGIIIb and
increased pathogen loads in the cecal mucosa at J50 (Figures
4K–4L). Interestingly, we found elevated levels of Il22 and
Reg3b expression in the cecal mucosa of IFN-g-impaired mice
(Figure 4M). Although the cellular source of mucosal IL-22 during
oral Salmonella infection is yet poorly defined, the contribution of
CD3+ T cells during later stages of acute inflammation has been
reported (Godinez et al., 2008). To this end, we observed that the
IFN-g-deficient cecal mucosa harbored increased proportions
of IL-22-producing Thy1+ CD3+ gd T cells (Figures S3H–S3M).
Next, we analyzed whether IL-22 deficiency would affect resolu-
tion kinetics. While the IL-22/REGIII antimicrobial axis was
clearly involved in mucosal pathogen control during therapy,
we observed no significant difference in the pathology of antibi-
otic-treated mice under IL-22-sufficient or -deficient conditions
(Figures 4N–4O). These data suggest that IFN-g has two effects
during antibiotic therapy, i.e., delaying resolution of mucosal
inflammation and coordinating pathogen restriction at systemic
sites, where genetic IFN-g deficiency permits higher persister
loads. The gut mucosa might remain protected by (compensa-
tory) epithelial IL-22/REGIII responses even in IFN-g-deficient
mice. The cellular source of mucosal IFN-g and its downstream
mechanism of regulation remain, however, to be elucidated.
Impaired IFN-g Signaling Promotes Granulocyte and
Macrophage Plasticity during Therapy
IFN-g is an important stimulus for immune activation and
differentiation. We therefore asked how IFN-gwould affect cecal
lamina propria myeloid cell composition. In line with the acceler-
ated remission kinetics, mice with compromised IFN-g signaling
harbored reduced Ly-6G+ neutrophil numbers in the cecal
mucosa after 2 days of therapy (Figures 5A and 5B). The propor-
tion of Ly-6C+MHCII+MCint, another archetypal subset of severe
acute inflammation, was also reduced (Figures 5C and 5D). This
went along with the accumulation of differentiated Ly-6C–
MHCII+ mac, a cell type typically observed in homeostasis and
advanced remission. We therefore speculated that the resolving
histopathology observed under paucity of IFN-g is in fact related
to the described plasticity of myeloids.
Next, we asked whether there was a functional link between
IFN-g signaling and mucosal MNP activity during remission.
Indeed, transcript levels of IL-1b, TNF, and iNOS were signifi-
cantly lowered in Ifng/, Ifngr1/ or IFN-g-neutralized animals
(Figures 5E and 5F). This went along with reduced levels of
total STAT1 proteins without detectable pY701 (Figure 5G).
Furthermore, IFN-g deficiency boosted the expression of
Arg1 and Retnla, which are hallmarks of a transcriptional pro-
gram determining M2 macrophage identity in wound healing
and tissue repair (Figure 5H; Murray and Wynn, 2011). These
observations would further support that IFN-g delays remission
by hindering the shift from inflammatory back to homeostatic
myeloids and the concomitant removal of pro-inflammatory
mediators.
Contribution of IFN-g-Producing Lymphoid Cells to
Delayed Recovery in Antibiotic-Treated Mice
Next, we aimed to define the cellular origin of mucosal IFN-g pro-
duction. Detailed analysis of the CD45+ Thy1+mucosal compart-
ment revealed two distinct IFN-g+ subsets after 2 days of therapy
(Figures 6A and S4A). IFN-g-producing CD3+ CD11b– cells were
mainly b TCR+ T cells that expressed CD8a, CD8b, and CCR6,
overall indicating an intraepithelial lymphocyte phenotype (Fig-
ure 6B). Some IFN-g+ T cells also expressed gd TCR and
NK1.1, indicating that NKT cells do also contribute (Figure 6B).
IFN-g-producing CD3– CD11b+ cells on the other hand were
predominantly classified as NK1.1+ Eomes+ NK cells with an
activated DX5+ CD27+ phenotype (Figure 6C). Absolute quantifi-
cation within the total CD45+ Thy1+ IFN-g+ pool revealed that the
IFN-g+ T cells were more abundant than the NK cell subset in the
cecal mucosa during resolution (Figure 6D).
To evaluate the contribution of these IFN-g-producing subsets
to delaying mucosal remission, we analyzed (1) animals in which
NK1.1-expressing cells were depleted during therapy (to elimi-
nate CD3+ NKT and CD3– NK cells), or (2) Tcrbd/ mice genet-
ically lacking CD3+ T cells, or (3) mice in which NK1.1-expressing
cells were depleted on a Tcrbd/ background. Importantly,
depletion of NK1.1+ cells only minimally altered the frequency
of IFN-g+ CD3+ cells (Figure S4B), while lack of the T cell
compartment in Tcrbd/ mice did not affect the pool of
CD11b+ NK cells (Figure S4C). This suggested that the two
main subsets of IFN-g producers can be studied separately
from each other. Next, we asked whether reduction in CD11b+
NK cell numbers or the lack of CD3+ T cells affected the resolu-
tion of inflammation during therapy. Neither depletion of NK1.1+
cells nor T cell deficiency alone was sufficient to alter remission
kinetics atJ50 (Figures 6E and 6F). Strikingly, when NK1.1
+ cells
were depleted on a Tcrbd/ background, the animals consis-
tently featured reduced mucosal pathology (Figures 6E and
6F). This penocopied the Ifng/ mice (Figures 4H and 4I).
In earlier work, we had found that IFN-g signaling controls
mucus excretion, presumably by signaling via the goblet cells’
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IFNGR (Songhet et al., 2011). This was used as a readout for
probing the intensity of mucosal IFN-g signaling during antibiotic
therapy. WT animals displayed lower numbers of mucus-filled
vacuoles than NK-cell-depleted Tcrbd/ mice (Figure 6G).
Moreover, the lamina propria of these mice featured reduced
numbers of Ly-6G+ cells, and the cecal mucosa expressed
less Il1b (Figures 6H and 6I). Put together, this identifies IFN-g-
producing T, NKT, and NK cells as key players with partially
redundant function that control the kinetics ofmucosal remission
from acute diarrhea during antibiotic therapy.
DISCUSSION
The mechanisms controlling re-establishment of homeostasis
after microbial gut infections still remain elusive. A better under-
standing of the temporal and molecular parameters of recovery
from acute intestinal disease is vital and urgent, especially in
therapy of immunocompromised patients and children (Saleh
and Elson, 2011; Scallan et al., 2015; Schwille-Kiuntke et al.,
2015). Here, we analyzed remission during antibiotic therapy
in an acute S. Typhimurium enterocolitis model. High-dose
ciprofloxacin therapy efficiently eliminates the pathogen from
the gut lumen, while1%–10%of the bacteria survive in an anti-
biotic-tolerant state within the intestinal tissue and the mLN.
Significant (though incomplete) remission of mucosal pathology
occurs during the first 2 days of antibiotic therapy, reducing the
inflammation by about 50% (J50). The restoration of epithelial
integrity (Figures 2H, 2J, and 2K) seems to precede the clear-
ance of highly accumulated PMNs (Figures S2C, 2F, S1D, and
S1E) and the restoration of homeostatic non-inflammatory
MNP populations (Figures 3D–3I). Remission kinetics at this
stage are limited by IFN-g released frommucosal T and NK cells.
Strikingly, ablation of IFN-g signaling (1) accelerated the clear-
ance of neutrophils, (2) promoted thematuration and polarization
of intestinal MNPs toward homeostasis, (3) attenuated STAT1
signaling, and (4) boosted the antimicrobial host defense via
IL-22/REGIIIb. These findings may explain why antibiotics fail
to relieve enteropathy in human patients (Onwuezobe et al.,
2012). Moreover, such IFN-g dependent mechanisms may be
of broad relevance to other pathogenic infections (Burrack and
Morrison, 2014; Chiang et al., 2012) and other inflammatory
disorders such as allergy, renal fibrosis, neurodegenerative
diseases, or cancer (Janakiram et al., 2011; Levy and Serhan,
2014; Luo et al., 2013).
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Figure 5. Ablation of IFN-g Signaling Promotes Myeloid Plasticity
Bl6 and knockout mice were infected as in Figure 4E.
(A and B) Ly-6G+ neutrophils.
(C and D) Monocyte waterfall cells. MC: Ly-6Chi MHCII–/ MCint: Ly-6C+ MHCII+/ mac: Ly-6C– MHCII+.
(E and F) Il1b, Tnf (E), and Nos2 (F) transcript levels.
(G) Western blot analysis of pY701 STAT1, STAT1, and GAPDH. 0, below detection limit.
(H) Arg1 and Retnla transcript levels.
Summary graphs show five to six individual mice pooled from two to three independent experiments as mean ± SD. Statistical significance was analyzed via the
Mann-Whitney U test. +cip, oral ciprofloxacin treatment.
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Bacterial infections and food-borne diarrhea continue to
cause significant morbidity and mortality worldwide (GBD 2013
Mortality and Causes of Death Collaborators, 2015). In fact,
diarrheal diseases rank among the top 10 causes of ‘loss in
disability-adjusted life years’ (DALY; Murray et al., 2015), and
non-typhoidal Salmonella spp. belong to the most prominent
food-borne agents across the globe (Kirk et al., 2015). Strikingly,
people recovering from the initial, acute disease are prone to
continued sequelae, explaining the high disease burden inflicted
by diarrheal diseases. The underlying mechanisms are not yet
well understood. Our findings indicate that antibiotic therapy of
murine S.Tm enterocolitis might offer a model to study such
mechanisms. In this model, the pathogen is eliminated from
the lumen as early as 3 hr after treatment (Kaiser et al., 2014),
while complete resolution is only achieved by 7–9 days of ther-
apy (Figure 1G). Molecular inspection unraveled that a set of
genes remained highly expressed throughout the treatment (Fig-
ures 2A and 2E). We refuted a role for (1) residual luminal S.Tm
that may provoke sustained immune activation at the mucosal
interface (Figures 1C, 2H, and S1F); (2) blooms of pathogenic
members of the residential microbial community (Figures 2I,
S1F, S5A, and S5B; Table S2); and (3) prolonged gut barrier
dysfunction (Figures 2J and 2K) as implicated in chemical colitis
(Wirtz et al., 2007). Much rather, residual inflammation well after
antibiotic-mediated pathogen-clearance resulted (at least in
part) from IFN-g-dependent immune dysregulation. It is tempting
to speculate that this mechanism may enhance susceptibility to
subsequent infections (Osborne et al., 2014) and/or contribute to
the high prevalence of ‘‘post-infection’’ gastrointestinal disor-
ders, such as irritable bowel syndrome (Koh et al., 2012).
To addresswhat elicits the pro-inflammatory program sustain-
ing mucosal inflammation, we speculated that persistent S.Tm
surviving in the tissue of antibiotic-treated mice might be
involved. Indeed, such persisters have been identified (Claudi
et al., 2014; Diard et al., 2014). In line, about 1% of bacteria sur-
vived therapy within the mucosal tissue by day 5 p.i. (Figures 4A
and 4B). As S.Tm persisters are predominantly lodged within
patrolling CD11c+ MNPs (Helaine et al., 2014; Kaiser et al.,
2014), we initially hypothesized that these persisters may stimu-
late the residual inflammation and that this may cease if per-
sisters were eliminated. We found, however, that resolution ki-
netics were left unchanged if persister loads were lowered by
combined antibiotic treatment (Figures 4H and 4I; Figure S5C),
or increased in mice with impaired antimicrobial host defense
during early recovery (Figures 4K–4O). Thus, 10-fold changes
in persister loads do not seem to affect resolution kinetics. How-
ever, this cannot formally rule out that (besides IFN-g) persisters
may also contribute to slowing down remission.
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Figure 6. IFN-g-Producing Lymphoid Cells Delay Remission in Antibiotic-Treated Mice
(A–D) Mice were infected as in Figure 4E. IFN-g production (A and D) and surface marker expression by (B) CD3+ CD11b– and (C) CD3– CD11b+ cells.
(E–I) Bl6 or Tcrbd/mice were infected as in Figure 1 and additionally treated with aNK1.1-depleting antibodies during therapy, as indicated. (E) Histopathology
scoring of cecal tissue. (F) H&E-stained cecal tissue sections. Scale bar, 100 mm. (G) Mucus-filled vacuole retention (black arrowheads). Sections originate from
Figures 6E and 6F. (H) Ly-6G+ neutrophils. (I) Il1b transcript levels.
Summary graphs show five to seven individual mice pooled from two to three independent experiments as mean ± SD. Statistical significance was analyzed via
the Mann-Whitney U test. +cip, oral ciprofloxacin treatment; n.s., not significant; aNK1.1, depleting antibody for NK1.1+ cells.
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While IFN-g is induced by >100-fold during the first day of
infection, possibly to modulate innate MNP function, its release
from mucosal T and NK cells was found to delay resolution.
This was supported by several lines of evidence. (1) IFN-g was
dispensable for mounting mucosal inflammation at day 1 p.i.
(Figure 4H; A.A.M., unpublished data); (2) cytokine neutralization
during therapy resulted in comparable resolution kinetics as
observed in mice with genetic IFN-g defficiency (Figures 4E–4I
and 5); (3) reduced IFN-g levels attenuated canonical STAT1
signaling (Figure 5G); and (4) cytokine deficiency permitted
mucosal remodeling of Ly-6G+ neutrophils and intestinal MNPs
(Figure 5). These findings are in line with previous studies
implicating IFN-g in disease resolution and tissue scarring in
Chlamydia trachoma (Hu et al., 2013), STAT1-associated patho-
physiology in ulcerative colitis (Schreiber et al., 2002), tissue-
specific cytokine patterns in remissive pediatric Crohn’s disease
(Agnholt et al., 2003; Sylvester et al., 2014), and retuned respon-
siveness of macrophages in respiratory exacerbations (Kaur
et al., 2015). While IFN-g is clearly important, we cannot exclude
that other factors (e.g., TNF, IL-6, IL-17A), the remaining
persisters or (at later stages) adaptive immune responses may
also affect remission. Our datawould also be in linewith compro-
mised migratory CD103+ DC function observed in severe long-
term lymphadenopathy after acute Y. pseudotuberculosis infec-
tion (Fonseca et al., 2015).
Together, our study explains why mucosal inflammation may
remain during antibiotic therapy and provides key insights into
how the innate immune system reshapes the mucosal milieu
after acute NTS challenge. Monitoring of pathogen shedding
is clearly insufficient for probing the resolution of disease and
should be supplemented by data on key inflammatory markers
like IFN-g. Such improved diagnostic protocols would seem
pivotal for analyzing remission in human patients, in particular,
in cases with sustained enteropathy. Understanding the mecha-
nisms that drive remission to homeostasis will enable a next gen-
eration of therapeutic approaches that may combine antibiotics
with the boosting of cell-mediated cytotoxicity (Maltez et al.,
2015) and/or the collateral resolution of inflammatory mediators.
EXPERIMENTAL PROCEDURES
Animals
C57BL/6J SFP, C57BL/6JGNO, B6.129P-Cx3cr1tm1LittJ, B6.129S7-Ifngtm1Ts/J,
B6.129S5-Il22tm1Lex; B6.129P2-Tcrbtm1MomTcrdtm1Mom/J; B6.129S7-
Ifngr1tm1Agt/J mice were housed and bred under SPF conditions in individually
ventilated cages (IVCs) in RCHCI and EPIC, ETH, Zu¨rich, and in LASC, UZH,
Zu¨rich, respectively. Mice were used at an age of 6–12 weeks, and Ifng/ or
Il22/ animals included littermates. All animal procedures have been per-
formed as approved by the Kantonales Veterina¨ramt (223/2010, 222/2013).
Infections, Bacteria, Antibiotic Therapy, and Antibody Treatment
Mice were orally pre-treated with 20 mg streptomycin (Applichem) and in-
fected with SB300, a wild-type Salmonella enterica ssp. enterica serovar
Typhimurium SL1344 derivative (Barthel et al., 2003). Ciprofloxacin (Ciproxine
500 mg, Bayer) was applied in 2.5-mg dosage per os twice daily (‘‘+cip’’; Kai-
ser et al., 2014). Ceftriaxone (Rocephin 1 g, Roche) was supplemented daily
1.25 mg intraperitoneally (i.p.). Of note, 12 hr after the first antibiotic treatment,
animals were transferred into fresh cages to avoid re-contamination via the
oral route. Bacterial loads in stool and organs were determined by plating on
MacConkey agar (Oxoid; 50 mg/ml streptomycin). Cecal tissue lysates were
prepared after 30 min incubation in 400 mg/ml gentamycin/PBS and six
subsequent washes in PBS. Anti-IFNg (Bio X Cell; R4-6A2; 500 mg twice daily),
anti-IL-22 (eBioscience; IL22JOP; 500 mg once), rat IgG2a k (eBioscience;
500 mg once), and anti-NK1.1 (Bio X Cell; PK136; 250 mg daily); antibodies
were administered i.p. during ciprofloxacin therapy.
Histopathology and Immunohistochemistry
Ceca were excised at the entry of the ileo-cecal junction and weighed. The
cecal index was defined as (total body weight)/(organ weight). Cecal tissue
was frozen in Tissue Tek OCT medium (Sysmex). 10-mm cryo-sections were
H&E stained using COT 20 (Medite). Pathology was scored in a blinded fashion
(Barthel et al., 2003). The severity is indicated as uninflamed (–), mild (+),
moderate (++), and profound (+++) colitis. For Tyr701-pSTAT1 staining (Cell
Signaling Technology), tissue samples were fixed in 4% paraformaldehyde
for 5 days at room temperature and embedded in paraffin. Approximately
2-mm tissue sections were deparaffinized, rehydrated, and boiled at 100C
with EDTA for antigen retrieval. Immunohistochemistry (IHC) staining was
done on an automated BOND-MAX stainer using the Bond Polymer Refine
Detection kit (Leica).
In Vivo Epithelial Barrier Permeability
DSS controls received 2% DSS (TdB Consultancy) in drinking water as
described (Wirtz et al., 2007). Serum albumin was quantified from cecal con-
tent using a mouse albumin ELISA (Bethyl Laboratories), an ABTS-based sub-
strate and spectroscopy (Spectramax Plus, Molecular Devices). 15 mg 4 kDa
FITC-labeled dextran (TdB Consultancy) was applied to the same animals
(Chassaing et al., 2015). FITC fluorescence intensity was measured in serum
(485/535 nm; Victor 3, PerkinElmer).
Real-Time qPCR
The cecum mid-segments were rinsed in cold PBS and snap-frozen in
RNAlater (QIAGEN). Flow-cytometry-sorted cells were directly processed.
Total RNAwas extracted via RNeasyMini or Micro kits (QIAGEN), respectively.
1 mg RNA (Nanodrop) was reverse-transcribed using the RT2 HT First Strand
cDNA Kit (QIAGEN). Custom RT2 Profiler PCR Arrays and Primer Assays
(QIAGEN) were run with RT2 SYBR Green ROX FAST (QIAGEN) on a 7900
HT Fast Real-Time PCR equipped with an SDS 2.2.1 software (Applied
Biosystems). Relative transcript levels were normalized to Actb. The
upper limit of Cq was fixed to 35 cycles. All procedures were performed ac-
cording to the manufacturer’s instructions. Hierarchical clustering identified
gene clusters with similar expression trends using ‘‘ward’’ as the clustering
method and ‘‘correlation’’ as ameasure of distance. 1,000 bootstrap replicates
were generated and the five clusters were determined at 0.05 significance
level.
Confocal Microscopy
If indicated, animals were infected with WT S.Tm harboring PssaG-gfp (Hap-
felmeier et al., 2005). Sample preparation and confocal microscopy were per-
formed as described (Stecher et al., 2007). Sections were stained with SYTOX
Green (Life Technologies), a-S.Tm LPS O-antigen group B factor (Difco Labo-
ratories), goat a-rabbit-Cy3 (Jackson ImmunoResearch Laboratories), AF647-
conjugated phalloidin (Molecular Probes), or DAPI (Sigma). A Zeiss Axiovert
200-m microscope with 103–1003 objectives, a spinning disc confocal laser
unit (Visitron) and two Evolve 512 EMCCD cameras (Photometrics) were used
for image recording, and Visiview (Visitron) for image analysis. S.Tm PssaG-
gfp was manually enumerated as GFP+ intracellular events in six to nine
non-consecutive 20-mm sections for each animal analyzed.
Cecal Lamina Propria Cell Isolation, Antibodies, and FlowCytometry
Excised cecawere opened longitudinally, placed into 4CPBS, and briefly vor-
texed. Tissues were cut into pieces and incubated twice in 5mMEDTA, 15mM
HEPES, 10% fetal calf serum (FCS) in PBS for 20 min at 37C, while mildly
shaking at 120 rpm. Samples were rinsed in RPMI (30% FCS), further sliced,
and digested for 60 min in RPMI (Bioconcept; 1 mg/ml Collagenase VIII
[Sigma], 0.2 mg/ml DNase I [Roche]). Cells were passed through a 70-mm
cell strainer (BD Biosciences), rinsed in RPMI, layered onto a NycoPrep
1.077 matrix (Progen), and centrifuged for 30 min at 400 3 g. The interface
was collected, washed with RPMI, and stained in 4C PBS (10% FCS,
0.02% NaN3). For detecting intrinsic cytokine production, isolated cells were
cultured for 5 hr in IMDM (Life Technologies; 10 mg/mL Brefeldin-A, 10%
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FCS, 10mMHEPES, 2mML-Glu, P/S). For intracellular cytokine detection, the
Foxp3 Staining Buffer Set (eBioscience) was used. Antibodies were from Bio-
Legend (CD45 [clone 30-F11], CD11b [M1/70], Thy1.2 [30-H.12], CD3 [17A2],
CD4 [RM4-5], CD19 [6D5], TCR b [H57-597], TCR gd [GL3], CD64 [X54-5/7.1],
CD11c [N418], MHCII [M5/114.15.2], Ly-6C [HK1.4], CD103 [2E7], Ly-6G
[1A8], IFN-g [XMG1.2], NK1.1 [PK136], CD8a [53-6.8], CD8b [YTS156.7.7],
CCR6 [29-2L17], CD49b [DX5], CD27 [LG.3A10]), from BD Biosciences (Si-
glec-F [E50-2440], Ly-6C [AL-21]), or from eBioscience
(Eomes [Dan11mag]). For live-cell labeling, SYTOX or LIVE/DEAD fixable
dead cell stains (Invitrogen) were included. Fc receptors were blocked with
purified anti-CD16/32 (clone 93). For quantitative analysis of the intestinal
microbiota, cecal contents were homogenized in PBS, snap-frozen, and
subsequently labeled with SYTOX Green (Life Technologies) and, if needed,
with a-S.Tm LPS O-antigen group B factor (Difco) and goat a-rabbit-
Cy5 (Jackson ImmunoResearch). All data were acquired on a LSRII flow
cytometer (BD Biosciences) and analyzed with FlowJo software (Tree Star).
Calculated total luminal S.Tm numbers were finally normalized to input content
weight.
Western Blot
REGIIIb proteins were detected in cecal contents as described (Stelter et al.,
2011). For STAT1 quantification, cecal tissue samples of equivalent weight
were homogenized in 1X reducing loading buffer (Red Loading Buffer Pack,
Cell Signal) supplemented with protease inhibitor cocktail tablets (Roche).
Nitrocellulose membranes (Whatman) were developed using polyclonal rabbit
a-RegIIIb antibody, rabbit a-phospho-STAT1 (Tyr701), rabbit a-STAT1 (Cell
Signal), rabbit a-GAPDH (Sigma), donkey a-rabbit-peroxidase conjugates
(GE Healthcare), and ECL kits (GE Healthcare). Commercial antibodies were
applied according to the manufacturers’ instruction. ImageJ 364 was used
for analysis.
Statistical Analysis
Statistical analyses were performed using non-parametric Mann-Whitney
U test. Tests were not significant p R 0.05 or significant *p < 0.05, **p <
0.01, ***p < 0.001.
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